<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01638598</url>
  </required_header>
  <id_info>
    <org_study_id>1310.3</org_study_id>
    <nct_id>NCT01638598</nct_id>
  </id_info>
  <brief_title>Single Rising Oral Doses of BI 1021958 in Healthy Chinese and Japanese Male Volunteers</brief_title>
  <official_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1021958 in Healthy Chinese and Japanese Male Volunteers (Placebo-controlled, Randomised and Double-blind Within Dose Groups)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Safety,tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BI 1021958 after
      single rising doses (SRD) in healthy Asian male volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number (%) of subjects with related adverse events.</measure>
    <time_frame>up to 17 days postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf (area under the concentration-time curve of BI 1021958 in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>up to day 4 postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve of BI 1021958 in plasma over the time interval from 0 up to the last quantifiable data point)</measure>
    <time_frame>up to day 4 postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-12 (area under the concentration-time curve of BI 1021958 in plasma over the time interval from the time point 0 until the time point 12 h)</measure>
    <time_frame>up to day 4 postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum measured concentration of BI 1021958 in plasma)</measure>
    <time_frame>up to day 4 postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-24 (area under the concentration-time curve of BI 1021958 in plasma over the time interval from the time point 0 until the time point 24 h)</measure>
    <time_frame>up to day 4 postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 1021958 dose group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subject to receive a tablet containing dose group 1 BI 1021958 single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 1021958 dose group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subject to receive a tablet containing dose group 2 BI 1021958 single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 1021958 dose group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subject to receive a tablet containing dose group 3 BI 1021958 single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 1021958 dose group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subject to receive a tablet containing dose group 4 BI 1021958 single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 1021958 dose group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subject to receive a tablet containing dose group 5 BI 1021958 single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>matching placebo</intervention_name>
    <description>matching placebo in each dose level</description>
    <arm_group_label>BI 1021958 dose group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Test drug</intervention_name>
    <description>BI 1021958</description>
    <arm_group_label>BI 1021958 dose group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>matching placebo</intervention_name>
    <description>matching placebo in each dose level</description>
    <arm_group_label>BI 1021958 dose group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Test drug</intervention_name>
    <description>BI 1021958</description>
    <arm_group_label>BI 1021958 dose group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Test drug</intervention_name>
    <description>BI 1021958</description>
    <arm_group_label>BI 1021958 dose group 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Test drug</intervention_name>
    <description>BI 1021958</description>
    <arm_group_label>BI 1021958 dose group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Test drug</intervention_name>
    <description>BI 1021958</description>
    <arm_group_label>BI 1021958 dose group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>matching placebo</intervention_name>
    <description>matching placebo in each dose level</description>
    <arm_group_label>BI 1021958 dose group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>matching placebo</intervention_name>
    <description>matching placebo in each dose level</description>
    <arm_group_label>BI 1021958 dose group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>matching placebo</intervention_name>
    <description>matching placebo in each dose level</description>
    <arm_group_label>BI 1021958 dose group 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Healthy males based upon a complete medical history, including a physical examination,
             vital signs (blood pressure, pulse rate), 12-lead ECG, and clinical laboratory tests

          2. Chinese ethnicity, Japanese ethnicity according to the following criteria Japanese;
             born in Japan, be a current Japanese passport holder, have lived outside of Japan &lt;5
             years, and have parents and grandparents who were all born in Japan Chinese; ethnic
             Chinese, born in China or ethnic Chinese born outside of China, and a descendent of 4
             ethnic Chinese grandparents who were all born in China

          3. Age within the range of 20 to 45 years

          4. Body mass index within the range of 18.5 and 25 kg/m2

          5. Signed and dated written informed consent prior to admission to the study in
             accordance with GCP and the local legislation.

        Exclusion criteria:

          1. Any finding of the medical examination (including Blood Pressure, Pulse Rate, ECG and
             Safety laboratory) deviating from normal and of clinical relevance

          2. Any evidence of a clinically relevant concomitant disease

          3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          4. Surgery of the gastrointestinal tract (except appendectomy)

          5. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          6. History of relevant orthostatic hypotension, fainting spells or blackouts.

          7. Chronic or relevant acute infections

          8. History of relevant allergy/hypersensitivity (including allergy/hypersensitivity to
             the study drug or its excipients)

          9. Intake of drugs with a long half-life (more than 24 hours) within at least 1 month or
             less than 10 half-lives of the respective drug prior to administration

         10. Use of drugs which might reasonably influence the results of the trial or that prolong
             the QT/QTc interval (based on the knowledge at the time of protocol preparation)
             within 10 days prior to administration

         11. Participation in another trial with an investigational drug administration within 2
             months prior to administration

         12. Smoker (more than 10 cigarettes or 3 cigars or 3 pipes/day)

         13. Inability to refrain from smoking on trial days

         14. Alcohol abuse (more than 30 g/day)

         15. Drug abuse

         16. Blood donation (more than 100 mL within 4 weeks prior to administration)

         17. Any laboratory value outside the reference range that is of clinical relevance

         18. Inability to comply with dietary regimen of trial site

         19. A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a
             QTc interval more than 450 ms), heart rate outside 45 to 90 bpm, or any other relevant
             ECG findings at screening

         20. A history of additional risk factors for TdP (e.g., heart failure, hypokalemia, family
             history of long QT Syndrome)

         21. Subjects considered unsuitable for inclusion by the investigator, e.g. because
             considered not able to understand and comply with study requirements, or have any
             condition which in the opinion of the investigator would not allow safe participation
             in the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1310.3.8201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2012</study_first_submitted>
  <study_first_submitted_qc>July 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2012</study_first_posted>
  <last_update_submitted>October 31, 2013</last_update_submitted>
  <last_update_submitted_qc>October 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

